

80000
60000
40000
20000
0
Plasma Concentrations
ng/mL
M3
MIN-102
0
4
8
12
16
20
24
Time (hr)

FIG. 1



Mouse
% Systemic exposure
0
20
40
60
80
MIN-102
M3
MIN-102
M3
MIN-102 administration
M3 administration

FIG. 2



Rat
% Systemic exposure
0
20
40
60
80
MIN-102
M3
MIN-102
M3
MIN-102 administration
M3 administration

FIG. 3



y = 0.0341x - 1104.1
R² = 0.975
14000
12000
10000
8000
6000
4000
2000
0
C_{min} ng/mL
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
AUC (ng·h/mL)

FIG. 4



MPC inhibition
% Basal BRET
200
180
160
140
120
100
-12
-10
-8
-6
-4
-2
Log (conc) M
Pioglitazone
MIN-102

FIG. 5

Hela




FIG. 6A




FIG. 6B



WT MDA MB231
OCR (pmol/min)
500
400
300
200
100
0
0
50
100
Minutes
Maximum OCR relative to vehicle
1.5
1.0
0.5
0.0
****
**
**
WT vehicle
WT MX 2.5 uM
WT MX 5 uM
WT MX 10 uM

FIG. 7A

KO MDA MB231




FIG. 7B




FIG. 8



% Systemic Exposure
100
80
60
40
20
0
MIN-102
M3
MIN-102
M3
MIN-102 administration
M3 administration

FIG. 9



M-III and MIN-IV in cells incubates after 120 min
% degradation/recovery
140
120
100
80
60
40
20
0
A-B
B-A
A-B
B-A
MDCK-MDR1
MDCK mock
M-III
M-IV
Plastic/Membrane

FIG. 10